The first improvement over Lantus, according to Hobbs, is simply the length of time the insulin lasts. While Lantus lasts up to 24 hours per dose “with no pronounced peak,” Tresiba lasts considerably longer.
Tag: Tresiba
More than two years after dealing Novo Nordisk a surprising setback, the U.S. Food and Drug Administration has approved Tresiba (insulin degludec…
Todd Hobbs, the chief medical officer for North America at Novo Nordisk, knows diabetes from all angles: as a patient; as an endocrinologist (for ten years he ran a clinical practice focused on patients of all ages with diabetes); as an executive at a pharmaceutical company working to develop new treatments (he’s worked at Novo Nordisk since 2004); and as a parent (one of his six sons was diagnosed with type 1 at age five)
Novo Nordisk has been granted marketing authorization by the European Commission for a new injectable, Xultophy, for the treatment of Type 2 diabetes in adults.
Xultophy is the brand name for IDegLira, the first once-daily single injection combination of insulin degludec (Tresiba) and liraglutide (Victoza).
Data presented today at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen for type 2 diabetes patients.
Ryzodeg is a combination of two distinct insulin analogues , insulin degludec (Tresiba) and insulin aspart (Novolog) in the ratio of 70% and 30%, making it the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes.
Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN® YOUNG 1 trial. The study investigates once-daily Tresiba (insulin degludec) versus basal insulin Levemir (detemir), both in combination with bolus insulin Novolog (aspart) in a 52-week trial in children and adolescents with type 1 diabetes. This trial is the first to look into the long-term safety of Tresiba in children and adolescents (from age 1 to less than 18 years) and the results show that Tresiba in combination with Novolog (Novorapid) effectively improved long-term glycemic control.
IDegLira is a combination of Tresiba (insulin degludec), a once-daily basal insulin analogue with an ultra-long duration of action, and Victoza (liraglutide), the once-daily human GLP-1 analogue for the treatment of type 2 diabetes.
The U.S. FDA issued a Complete Response Letter regarding the New Drug Applications for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) informing Novo Nordisk that an application cannot be approved in its current form.
The European Commission has granted Novo Nordisk marketing authorizations for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults in 27 European Union member states.
The Japanese Ministry of Health, Labor and Welfare has approved Novo Nordisk's new combination insulin, Ryzodeg, for the treatment of diabetes.
Ryzodeg is a soluble formulation of Tresiba (insulin degludec), a once-daily new-generation basal insulin analogue with an ultra-long duration of action, and NovoRapid (insulin aspart which in the U.S. is marketed under the brand name NovoLog). Ryzodeg can be administered once or twice daily with the main meal(s).